Shenzhen Neptunus Bioengineering plans to acquire a 70% stake in a pharmaceutical company based in Hunan, China.

The company expects the acquisition to cost them up to $29.11m.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Korea Value Asset Management has acquired a 5% stake in biotech company ATGen.

“Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities.”

The 5% stake represents 0.56m shares of the target company.

Catalent plans to acquire Accucaps Industries to expand its over the counter (OTC) and prescription pharmaceutical softgel capabilities.

Pursuant to the acquisition, Accucaps’ employees will join Calatent’s global network of softgel technologies and its blistering, bottling and packaging facilities will be included into Catalent’s softgel development and manufacturing units.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The acquisition enables Catalent to increase its production by the addition of new products.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now